Michael Cecchini, Yale School of Medicine, New Haven, CT, discusses results from a Phase I/II study of olaparib and ramucirumab in metastatic, recurrent, or unresectable gastric (GC) and gastroesophageal junction (GEJ) adenocarcinoma (NCT03008278). Sponsored by the National Cancer Institute Experimental Therapeutics, the study consists of two phases. Firstly, a Phase I study with dose-escalation of olaparib in combination with standard dose ramucirumab (8mg/kg every bi-weekly) for gastric cancers. The tolerated dose in this combination for olaparib was 300mg twice daily. The second phase consists of dose expansion, evaluating efficacy and response rate. The response rate was 11% overall and 18% in the second-line population. This interview took place at the American Association for Cancer Research Annual Meeting 2022 in New Orleans, LA.
